Element Science

Element Science

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $261.1M

Overview

Element Science is a private, commercial-stage medical device company pioneering wearable technology for cardiovascular emergencies. Its core innovation is the Jewel® P-WCD, a sleek, adhesive-based wearable defibrillator that has received FDA approval and is available in limited U.S. markets. The company operates at the intersection of cardiovascular medicine and digital health, aiming to provide continuous, comfortable protection for at-risk patients. Its mission is to reduce mortality from sudden cardiac arrest through accessible, user-centric wearable technology.

Cardiovascular

Technology Platform

Wearable Patch Cardioverter Defibrillator (P-WCD) platform integrating adhesive-based wearable design, arrhythmia detection algorithms, and therapy delivery for sudden cardiac arrest protection.

Funding History

3
Total raised:$261.1M
Series D$145M
Series C$76.6M
Series B$39.5M

Opportunities

The large addressable market of patients at temporary risk for sudden cardiac arrest presents a significant opportunity.
The Jewel's improved comfort and discreet design could drive higher patient compliance and expand market penetration compared to older, bulkier wearable defibrillators.
The continuous data collection capability also opens future avenues in remote patient monitoring and predictive analytics.

Risk Factors

Key risks include challenges in scaling commercialization, securing broad insurance reimbursement, and competing against established medical device companies.
Additional risks involve potential real-world performance issues post-FDA approval and the ongoing regulatory burdens associated with a Class III life-sustaining medical device.

Competitive Landscape

Element Science competes directly with traditional wearable cardioverter defibrillator manufacturers like Zoll Medical (a subsidiary of Asahi Kasei). It also faces indirect competition from implantable cardioverter defibrillator (ICD) makers (Medtronic, Boston Scientific, Abbott) and must demonstrate its value proposition for the temporary-risk patient population where ICDs are not yet indicated.